Efficacy and toxicity of PD-1 inhibitor combined with induction chemotherapy for locally advanced laryngeal and hypopharyngeal cancers.

Tingting Zhao, Wan Liu, Rong Yan, Yanjie Ma, Xudong Wang, Minghui Wei

Abstract read

In one paragraph

Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tingting ZhaoDepartment of Head and Neck Oncology, Tianjin Medical University Cancer Institute & Hospital, Key Laboratory of Basic and Translational Medicine on Head & Neck Cancer, Tianjin, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer Tianjin 300060, China.

Wan LiuDepartment of Head and Neck Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Shenzhen 518116, Guangdong, China.

Rong YanDepartment of Otorhinolaryngology, Shenzhen People's Hospital, The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology Shenzhen 518020, Guangdong, China.

Yanjie MaDepartment of Head and Neck Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Shenzhen 518116, Guangdong, China.

Xudong WangDepartment of Head and Neck Oncology, Tianjin Medical University Cancer Institute & Hospital, Key Laboratory of Basic and Translational Medicine on Head & Neck Cancer, Tianjin, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer Tianjin 300060, China.

Minghui WeiDepartment of Head and Neck Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Shenzhen 518116, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the efficacy, toxicity, and voice rehabilitation outcomes of PD-1 inhibitors combined with induction chemotherapy (PCIC) compared to induction chemotherapy (IC) alone.

methodsA retrospective analysis was conducted on 250 patients with stage III/IVA squamous cell carcinoma of the larynx/hypopharynx treated between June 2021 and December 2023. After 1:1 propensity score matching, 216 patients (108 per group) were analyzed. Both groups received platinum-based induction chemotherapy, with the PCIC group receiving an additional PD-1 inhibitor, toripalimab. Efficacy was evaluated based on response rates and survival outcomes, while toxicity profiles and voice rehabilitation were assessed.

resultsThe PCIC group had significantly higher complete remission rates (81.48% vs. 65.74%; P = 0.021) and improved 1-year overall survival (62.96% vs. 49.07%; P = 0.040). The incidence of neutropenia and nausea was higher in the PCIC group (P < 0.05). Voice quality assessments showed worse objective vocal grade but better patient-perceived vocal quality in the PCIC group (both P < 0.05).

conclusionThe combination of PD-1 inhibitors with induction chemotherapy improve remission rates and survival in patients with locally advanced laryngeal and hypopharyngeal cancers. However, increased toxicity and voice rehabilitation challenges highlight the need for comprehensive patient support during treatment.

Indexed as

hypopharyngeal cancerinduction chemotherapylaryngeal cancerPD-1 inhibitorssurvival outcomestoxicity profiles

Identifiers

PMID40520879

DOI10.62347/HVRH6856

PMCPMC12163456

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.